Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 16/20 | 1.00 |
| ▸ | PIK3C2G | O75747 | 15/20 | 1.00 |
| ▸ | AURKA | O14965 | 10/20 | 0.82 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.82 |
| ▸ | BRD4 | O60885 | 3/20 | 0.82 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.82 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.61 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.59 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19457444 | 0.93 | PIK3CD (0.88) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457393 | 0.93 | PIK3CD (0.86) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457382 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457386 | 0.90 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457409 | 0.89 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457389 | 0.89 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457443 | 0.88 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457442 | 0.87 | PIK3CD (0.91) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457445 | 0.87 | PIK3CD (0.91) | PIK3CDPIK3CGPIK3C2GAURKAAURKB | |
| SCHEMBL19457440 | 0.87 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3C2GAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440084-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| WO-2017177092-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | PIK3CD 5/4885PIK3CG 7/4885PIK3C2G 28/4885 |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | PI4KA, PI4KB, PIK3CA | PIK3CD 6/4885PIK3CG 12/4885PIK3C2G 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.